martes, 27 de febrero de 2018

Hematology/Oncology (Cancer) Approvals & Safety Notifications 2-26-2018

Approved Drugs > FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer



Hematology/Oncology (Cancer) Approvals & Safety Notifications

On February 26, 2018, the Food and Drug Administration approved abemaciclib (VERZENIO™, Eli Lilly and Company) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.  More Information.  

No hay comentarios:

Publicar un comentario